The estimated Net Worth of Associates Iv Llc Pro Quest... is at least $17.8 Миллион dollars as of 18 February 2014. Associates Quest owns over 333,333 units of Eagle Pharmaceuticals Inc stock worth over $17,795,188 and over the last 11 years Associates sold EGRX stock worth over $0.
Sign up
Associates Quest EGRX stock SEC Form 4 insiders trading
Associates has made over 1 trades of the Eagle Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Associates bought 333,333 units of EGRX stock worth $4,999,995 on 18 February 2014.
The largest trade Associates's ever made was buying 333,333 units of Eagle Pharmaceuticals Inc stock on 18 February 2014 worth over $4,999,995. On average, Associates trades about 333,333 units every 0 days since 2014. As of 18 February 2014 Associates still owns at least 4,770,828 units of Eagle Pharmaceuticals Inc stock.
You can see the complete history of Associates Quest stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Eagle Pharmaceuticals Inc
Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein и Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.
What does Eagle Pharmaceuticals Inc's logo look like?
Complete history of Associates Quest stock trades at Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc executives and stock owners
Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Scott Tarriff,
Chief Executive Officer, Director -
David Pernock,
President, Chief Operating Officer -
David M. Pernock,
Exec. VP of Operations -
Brian Joseph Cahill,
Chief Financial Officer -
Michael Graves,
Independent Chairman of the Board -
Steven Ratoff,
Independent Director -
Robert Glenning,
Independent Director -
Jennifer Simpson,
Independent Director -
Richard Edlin,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Brian Cahill,
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer -
Debra M. Hussain,
Sr. VP & Head of Commercial -
Reiner Nowak,
Exec. -
Dr. Gaozhong Zhu Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Dr. Valentin R. Curt M.D.,
Sr. VP of Clinical Drug Devel. -
John Kimmet,
Exec. VP of Marketing Oncology & Acute Care -
Michael Shawn Moran,
Exec. VP, Chief Commercial Officer & Principal Operating Officer -
Daniel O'Connor,
Exec. VP, Chief Strategy Officer & Head of Corp. Devel. -
Ryan Debski,
Exec. VP, Gen. Counsel & Chief Compliance Officer -
Steven L. Krill,
Chief Scientific Officer -
Pete A. Meyers,
Chief Financial Officer -
David E Riggs,
Chief Financial Officer -
Investments Iv, L.P.Pro Que...,
-
Sander A Flaum,
Director -
Douglas L Braunstein,
Director -
Executive Capital Lphec Man...,
-
Alain Schreiber,
Director -
Jay Moorin,
Director -
Management Llc Pro Quest In...,
-
Financial Llc Pro Quest Inv...,
-
Paul Bruinenberg,
Chief Medical Officer -
Associates Iv Llc Pro Quest...,
-
Judith Ng Cashin,
Chief Medical Officer -
Luciana Borio,
Director -
Michael Shawn Moran,
EVP, Chief Commercial Officer